CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 322 enrolled
Drug / intervention
ACRYSOF® IQ Extended Depth of Focus IOL +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03010254
NCT03010254N/ACompleted
CompareCT.gov

A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSOF® IQ Extended Depth of Focus (EDF) IOL

Alcon Research·interventional·Posted Jan 5, 2017·Updated Apr 7, 2020

In Brief

A clinical study evaluating ACRYSOF® IQ Extended Depth of Focus IOL, ACRYSOF® IQ Monofocal IOL, and 1 other intervention for Cataract. Completed, enrolled 322 participants across 21 sites in 4 countries.

Detailed Summary

The purpose of the study is to demonstrate the safety and performance of the ACRYSOF® IQ EDF IOL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesAustralia, Canada, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 5, 2017
Enrollment StartMar 21, 2017
Primary CompletionAug 17, 2018
Study CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.5 years ago

Interventions

ACRYSOF® IQ Extended Depth of Focus IOLdevice

Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject

ACRYSOF® IQ Monofocal IOLdevice

Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject

Cataract surgeryprocedure

IOL bilateral implantation